Literature DB >> 7571213

Adenocarcinoma of the rete testis.

M Sánchez-Chapado1, J C Angulo, G P Haas.   

Abstract

To date, no studies have evaluated adenocarcinoma of the rete testis statistically, because reports have been limited to single cases or series of 2 cases only. Univariate and multivariate analyses on disease-free survival have been performed after combining all data available in the literature with our own. Information about disease-free survival has been collected in 38 patients. As many as 40% of them died within the first year of diagnosis. Three and 5-year disease-free survival was 49% and 13%, respectively. We have not detected any difference in survival between age groups or side of the lesion. Similarly, statistical difference cannot be proved between survival of tumors with nodular infiltrating or cystic growth pattern, although it has been suggested that these two varieties represent different tumor types from a gross and microscopic morphologic point of view. Univariate analysis reveals that tumor stage, tumor size, and therapy may have an influence on survival. Tumors that are organ-confined and small lesions (testicular mass < 5 cm in maximum diameter) behave definitely better than those disseminated at diagnosis or of a bigger size. Surprisingly, tumor size is not associated with tumor stage or histologic growth pattern (nodular infiltrating versus predominantly cystic). With regard to therapy, cases in which RPLND has been performed as part of the therapy behave better in univariate analysis, while patients who receive radiation do worse. Most probably these facts reflect that patients with clearly advanced disease where local control cannot be achieved by surgery tend to undergo palliative treatment by radiation. On the other hand, RPLND tends to be performed in patients in whom there is no evidence of distant spread. Therefore, it would really be the primary stage that would set the prognosis rather than the consequent treatment, and neither radiation therapy nor RPLND would be true independent variables. Similarly, no significant difference is observed when patients receive chemotherapy. Cox's regression analysis reveals size of the testicular tumor as the only independent predictor of survival. Stage at diagnosis does not have an influence by itself and neither does any form of therapy. In this sense, the negative effect of radiotherapy is eliminated. We are aware that the results drawn from a literature review are far from ideal, but there is not enough evidence to suggest an optimal sequence of treatment for this rare malignancy. To date, no effective chemotherapy has been found. Whenever the tumor is resectable, there appears to be merit in an RPLND.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7571213     DOI: 10.1016/S0090-4295(99)80257-X

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  16 in total

1.  Multilocular spermatocele: a case report.

Authors:  H Yagi; M Igawa; H Shiina; K Shigeno; T Yoneda; Y Wada
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  [Carcinoma of the rete testis with lymphogenous metastasis: multimodal treatment].

Authors:  T Klotz; B Schwindl; M J Mathers
Journal:  Urologe A       Date:  2012-03       Impact factor: 0.639

Review 3.  Management of non-germinal testicular tumors.

Authors:  Michael C Risk; Christopher R Porter
Journal:  World J Urol       Date:  2009-03-26       Impact factor: 4.226

4.  Primary adenocarcinoma of the epididymis: the therapeutic role of retroperitoneal lymphadenectomy.

Authors:  Michal Staník; Jan Doležel; Daniel Macík; Antonín Krpenský; Radek Lakomý
Journal:  Int Urol Nephrol       Date:  2012-03-01       Impact factor: 2.370

5.  Adenocarcinoma of rete testis with widespread liver metastasis.

Authors:  Zhenyu Yang; Chang Sheng; Lei Cao; Dengshan Wang
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

6.  Primary adenocarcinoma of the rete testis with elevated serum CA19-9 antigen levels.

Authors:  Hiroyuki Kitano; Kazuhiro Sentani; Keisuke Goto; Yohei Sekino; Ryoken Yamanaka; Keiji Nagasaka; Yoshinori Shigematsu; Kanao Kobayashi; Tetsutaro Hayashi; Wataru Yasui; Jun Teishima
Journal:  Int Cancer Conf J       Date:  2020-08-09

7.  Primary adenocarcinoma of the rete testis.

Authors:  P Perimenis; A Athanasopoulos; M Speakman
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

8.  Primary adenocarcinoma of the rete testis with preceding detection of unilateral hydronephrosis.

Authors:  Byung Woo Lee; Min Gu Park; Dae Yeon Cho; Seok San Park; Jeong Kyun Yeo
Journal:  Korean J Urol       Date:  2013-06-12

9.  Papillary adenocarcinoma of rete testis mimics inflammatory lump: a case report.

Authors:  Che-An Wu; Yung-Hsiang Chen; Kee-Ming Man; Jui-Lung Shen; Wen-Chi Chen
Journal:  Case Rep Urol       Date:  2011-09-29

10.  A case of adenocarcinoma of the rete testis accompanied by focal adenomatous hyperplasia.

Authors:  Xu-Yong Lin; Juan-Han Yu; Hong-Tao Xu; Liang Wang; Chui-Feng Fan; Yang Liu; En-Hua Wang
Journal:  Diagn Pathol       Date:  2013-06-24       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.